Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines,anti-PD-1 and poly I:C
10.1016/j.jpha.2023.04.012
- Author:
Ping ZHU
1
;
Shi-You LI
;
Jin DING
;
Zhou FEI
;
Sheng-Nan SUN
;
Zhao-Hui ZHENG
;
Ding WEI
;
Jun JIANG
;
Jin-Lin MIAO
;
San-Zhong LI
;
Xing LUO
;
Kui ZHANG
;
Bin WANG
;
Kun ZHANG
;
Su PU
;
Qian-Ting WANG
;
Xin-Yue ZHANG
;
Gao-Liu WEN
;
Jun O.LIU
;
Thomas-John AUGUST
;
Huijie BIAN
;
Zhi-Nan CHEN
;
You-Wen HE
Author Information
1. Department of Clinical Immunology,Xijing Hospital,Department of Cell Biology,National Translational Science Center for Molecular Medicine,Fourth Military Medical University,Xi'an,710032,China
- Keywords:
Glioblastoma multiforme;
DC vaccine;
Tumor-associated antigens;
Neoantigens
- From:
Journal of Pharmaceutical Analysis
2023;13(6):616-624
- CountryChina
- Language:Chinese
-
Abstract:
Glioblastoma(GBM)is a lethal cancer with limited therapeutic options.Dendritic cell(DC)-based cancer vaccines provide a promising approach for GBM treatment.Clinical studies suggest that other immu-notherapeutic agents may be combined with DC vaccines to further enhance antitumor activity.Here,we report a GBM case with combination immunotherapy consisting of DC vaccines,anti-programmed death-1(anti-PD-1)and poly I:C as well as the chemotherapeutic agent cyclophosphamide that was integrated with standard chemoradiation therapy,and the patient remained disease-free for 69 months.The patient received DC vaccines loaded with multiple forms of tumor antigens,including mRNA-tumor associated antigens(TAA),mRNA-neoantigens,and hypochlorous acid(HOCl)-oxidized tumor lysates.Furthermore,mRNA-TAAAs were modified with a novel TriVac technology that fuses TAAs with a destabilization domain and inserts TAAs into full-length lysosomal associated membrane protein-1 to enhance major histo-compatibility complex(MHC)class Ⅰ and Ⅱ antigen presentation.The treatment consisted of 42 DC cancer vaccine infusions,26 anti-PD-1 antibody nivolumab administrations and 126 poly I:C injections for DC infusions.The patient also received 28 doses of cyclophosphamide for depletion of regulatory T cells.No immunotherapy-related adverse events were observed during the treatment.Robust antitumor CD4+and CD8+T-cell responses were detected.The patient remains free of disease progression.This is the first case report on the combination of the above three agents to treat glioblastoma patients.Our results suggest that integrated combination immunotherapy is safe and feasible for long-term treatment in this patient.A large-scale trial to validate these findings is warranted.
